What is Silexan (lavender essential oil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Silexan?

Silexan is a standardized, proprietary oral preparation of essential oil derived from Lavandula angustifolia (lavender), formulated as 80 mg capsules and used as an anxiolytic and antidepressant agent. 1

Pharmaceutical Characteristics

Silexan represents a distinct pharmaceutical entity from aromatherapy lavender oil. It is:

  • A standardized oral formulation containing specific bioactive monoterpenoids (primarily linalool and linalyl acetate) extracted from lavender flowers 2
  • Administered orally at 80 mg daily, not via inhalation or topical application 1
  • Pharmacologically active through multi-target signaling networks affecting neurotransmitter systems, distinct from simple aromatherapy effects 3

Clinical Evidence Base

Anxiety Disorders

Silexan demonstrates robust anxiolytic efficacy across multiple controlled trials:

  • Significantly superior to placebo in reducing Hamilton Anxiety Rating Scale (HAM-A) scores in patients with subsyndromal anxiety and generalized anxiety disorder (GAD) 3
  • Comparable effectiveness to lorazepam 0.5 mg/day and paroxetine 20 mg/day in GAD patients 1
  • Efficacy evident within 2 weeks of treatment initiation, with optimal effects at 10 weeks 3
  • Baseline severity correlation: Greater symptom severity at baseline predicts larger treatment effects, though significant improvements occur across mild, moderate, and severe cases 4

Depression

In patients with mild to moderate major depressive disorder, silexan was superior to placebo and comparably effective to sertraline 50 mg/day after 8 weeks of treatment 5. The antidepressant profile includes:

  • Significant improvements in 5 of 9 Montgomery-Åsberg Depression Rating Scale (MADRS) items, particularly the cardinal symptoms: apparent sadness, reported sadness, and lassitude 5
  • Clinically meaningful effects on 7 of 9 MADRS items (adjusted mean differences >0.2 points) 5
  • Effectiveness in mixed anxiety-depressive disorder (MADD) 1

Sleep Quality

Silexan improves sleep primarily through its anxiolytic mechanism rather than direct sedative effects. Mediation analysis reveals that >98% of sleep improvement is mediated by anxiety reduction 6. This distinguishes it from traditional sedative-hypnotics.

Safety Profile

Silexan demonstrates exceptional tolerability:

  • Adverse effects limited to mild, transient gastrointestinal symptoms (primarily eructation) 1
  • No evidence of: sedation, drug interactions, dependence, abuse potential, sexual dysfunction, weight gain, or withdrawal symptoms 1
  • No sedation or cognitive impairment, making it suitable for daytime use without functional impairment 3

Mechanism of Action

Unlike aromatherapy lavender oil inhalation (which has weak evidence for procedural anxiety in cancer patients 7), oral silexan acts through:

  • Multi-target neurotransmitter modulation affecting GABA, serotonin, and other signaling pathways 2
  • Distinct pharmacological pathways from isolated monoterpenes, representing whole-oil matrix effects 2
  • Both anxiolytic and antidepressant mechanisms that are independent yet complementary 5

Clinical Context

Critical distinction: The evidence for silexan as an oral pharmaceutical preparation 5, 4, 1, 3 is entirely separate from evidence for lavender essential oil aromatherapy inhalation 7. The 2023 SIO-ASCO guidelines reference lavender oil inhalation for procedural anxiety in cancer patients with weak recommendations and low-quality evidence 7, which should not be conflated with the robust evidence base for oral silexan in psychiatric disorders.

Therapeutic Positioning

Silexan fills a therapeutic gap for patients with subsyndromal or mild-to-moderate anxiety and depression who may not require or tolerate conventional psychotropics 4. Its favorable safety profile, lack of dependence risk, and absence of sexual dysfunction or sedation make it particularly valuable for:

  • Early-stage anxiety disorders
  • Patients concerned about benzodiazepine dependence
  • Those experiencing sexual dysfunction or sedation from SSRIs
  • Individuals requiring anxiolytic therapy without cognitive impairment

References

Research

Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data.

European archives of psychiatry and clinical neuroscience, 2024

Research

Silexan in anxiety disorders: Clinical data and pharmacological background.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2018

Research

Effect of anxiolytic drug silexan on sleep - a narrative review.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.